A tan is a message. Sunlight damages skin cells, the cells answer by releasing a short peptide, and pigment cells read that peptide and make more dark melanin. The peptide is alpha-MSH and the receptor that reads it is MC1R. The whole cluster of tanning peptides, approved and unapproved, is a set of attempts to send that message without the sun. This page explains the pathway itself. It describes mechanism only; it makes no claim for any product and gives no advice.
The peptide: alpha-MSH
Alpha-melanocyte-stimulating hormone is a chain of 13 amino acids. It is not made on its own: the body builds a larger precursor protein, pro-opiomelanocortin (POMC), and cuts it into several active pieces. One is alpha-MSH. Another is ACTH, the pituitary hormone that drives cortisol. A third is beta-endorphin, one of the body's own opioids.
In skin, POMC is made by keratinocytes, the main cells of the outer layer. The key experiment on how sunlight switches it on was published in Cell in 2007 by Cui and colleagues (PMID 17350573). They showed that UV damage activates the tumour-suppressor protein p53, and p53 in turn directly switches on the POMC gene. Mice lacking p53 had no UV tanning response. The same pathway produced beta-endorphin, which the authors suggest "potentially contributes to sun-seeking behaviors".
That finding reframes a tan. It is not a sign of healthy skin; it is the downstream end of a DNA-damage alarm.
The receptors: MC1R to MC5R
Alpha-MSH and its relatives act on five receptors, named MC1R to MC5R:
| Receptor | Where it mainly sits | What it is known for |
|---|---|---|
| MC1R | Pigment cells (melanocytes) | Switches pigment production to dark eumelanin |
| MC2R | Adrenal gland | Responds to ACTH; drives cortisol |
| MC3R | Brain and other tissues | Energy balance |
| MC4R | Brain | Appetite, energy use, sexual function |
| MC5R | Glands in the skin and elsewhere | Secretion from exocrine glands |
The two that matter for the tanning peptides are MC1R, which produces the colour, and MC4R, which produces most of the side effects people notice from compounds that are not selective.
What MC1R does in a pigment cell
A pigment cell can make two kinds of melanin. Eumelanin is brown-black and absorbs UV well. Pheomelanin is red-yellow, absorbs UV poorly and can itself generate reactive molecules when exposed to light. When alpha-MSH activates MC1R, the cell shifts production toward eumelanin. That shift is what a tan is.
People whose MC1R gene carries weaker variants make more pheomelanin. The visible result is the familiar pattern of red hair, freckles and skin that burns. The invisible result is a higher melanoma risk. A 2012 meta-analysis of 1,639 melanoma patients and 1,342 controls in southern Europe found an odds ratio of 2.18 for carrying one red-hair-colour MC1R variant and 5.02 for carrying two (Ibarrola-Villava 2012, PMID 22464347). In families already carrying a high-risk CDKN2A mutation, one MC1R variant was associated with roughly double the melanoma risk (Fargnoli 2010, PMID 20189796). These are statements about inherited genes in populations, not about any drug; they show why this receptor is taken seriously in skin-cancer research.
Four approved drugs, and what they reveal
Four medicines on the market or in late development act on these receptors. Their labels and trials are the best-documented human evidence of what happens when the pathway is pushed from outside:
| Drug | Main target | Approved or tested for | What it does to skin, as reported |
|---|---|---|---|
| Afamelanotide (Scenesse) | MC1R | Erythropoietic protoporphyria (EPP), a rare light-sensitivity disease | Hyperpigmentation 4% vs 0% on placebo, per its label, which calls for regular skin examinations. See our afamelanotide page |
| Bremelanotide (Vyleesi) | Several, MC1R and MC4R most relevant | Low sexual desire in premenopausal women | Focal hyperpigmentation in 1% at up to eight doses a month, with higher risk under daily dosing, per its label. See melanotan 1 vs 2 |
| Setmelanotide (Imcivree) | MC4R, with 20-fold less activity at MC1R and MC3R | Rare genetic and hypothalamic obesity | Hyperpigmentation in 67% vs 0% on placebo over 14 weeks |
| Dersimelagon (in development) | MC1R, taken by mouth | EPP (phase 2 and later trials) | Freckles and skin hyperpigmentation among the most common adverse events |
Setmelanotide is the telling case. It was designed for the brain's appetite receptor, not for skin. Its FDA label (application NDA 213793, read on 28 September 2026) still records "generalized or focal increases in skin pigmentation" in "the majority" of treated patients, describes the effect as reversible when the drug stops, warns of darkening of existing moles and new moles, and instructs prescribers to perform a full-body skin examination before and during treatment. Even a small amount of activity at MC1R is enough to change skin colour visibly.
Dersimelagon shows the intended medical use of the pathway. In a randomized, placebo-controlled phase 2 trial in 102 people with EPP or X-linked protoporphyria, the time before the first warning symptom in sunlight rose by 53.8 minutes a day at the lower dose and 62.5 minutes at the higher dose, relative to placebo, over 16 weeks (Balwani 2023, NEJM, PMID 37043653; funded by Mitsubishi Tanabe Pharma). The point of the drug is protection from light for people for whom light is painful, delivered with monitoring. It is not a tanning product.
Where the melanotans fit
Melanotan I and melanotan II are laboratory copies of alpha-MSH, designed to be more stable and more potent than the natural peptide. Melanotan I acts mainly on MC1R; its approved form is afamelanotide. Melanotan II is shorter and ring-shaped and also reaches the brain receptors, which is why its early trials recorded effects on appetite and sexual function, and why its near-twin bremelanotide is a sexual-function drug. Neither is approved for tanning anywhere. The safety record, counted by source type, is on our melanotan side effects page, and the overview of the whole cluster is on tanning peptides.
Read against the table above, the approved drugs make one thing plain without any verdict on the unapproved ones: wherever this pathway is activated from outside, regulators require the skin to be watched. Every approved label that produces pigment change comes with skin examinations or mole warnings attached.
What this page does not cover
- Topical products. No approved cosmetic claims to activate MC1R, and a product claiming to "boost melanin" through this receptor would be making a drug claim. Peptides that appear on skincare labels act, if at all, on different targets; see what peptides do for skin.
- Doses or routes. None of the figures above is a dose, and none of these drugs is a tanning agent.
- Individual risk. MC1R genetics and mole changes are questions for a dermatologist, who can examine the skin in question.
Sources
- Cui R, Widlund HR, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007. PMID 17350573.
- Ibarrola-Villava M, et al. MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis. Eur J Cancer 2012. PMID 22464347.
- Fargnoli MC, et al. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer 2010. PMID 20189796.
- IMCIVREE (setmelanotide) prescribing information, NDA 213793, via openFDA drug label API, label effective 1 April 2026, read 28 September 2026.
- Balwani M, et al. Dersimelagon in Erythropoietic Protoporphyrias. N Engl J Med 2023. PMID 37043653. NCT03520036.
- Vyleesi and Scenesse label details as quoted and dated on our melanotan 1 vs 2 and afamelanotide pages.